Metabolism-related Long Non-coding RNAs (lncRNAs) As Potential Biomarkers for Predicting Risk of Recurrence in Breast Cancer Patients

Overview

Journal Bioengineered

Date 2021 Jul 13

PMID 34254565

Citations 10

Authors

Jian-Ying Ma

Shao-Hua Liu

Jie Chen

Qin Liu

Affiliations

Soon will be listed here.

Abstract

Metabolism affects the development, progression, and prognosis of various cancers, including breast cancer (BC). Our aim was to develop a metabolism-related long non-coding RNA (lncRNA) signature to assess the prognosis of BC patients in order to optimize treatment. Metabolism-related genes between breast tumors and normal tissues were screened out, and Pearson correlation analysis was used to investigate metabolism-related lncRNAs. In total, five metabolism-related lncRNAs were enrolled to establish prognostic signatures. Kaplan-Meier plots and the receiver operating characteristic (ROC) curves demonstrated good performance in both training and validation groups. Further analysis demonstrated that the signature was an independent prognostic factor for BC. A nomogram incorporating risk score and tumor stage was then constructed to evaluate the 3 - and 5-year recurrence-free survival (RFS) in patients with BC. In conclusion, this study identified a metabolism-related lncRNA signature that can predict RFS of BC patients and established a prognostic nomogram that helps guide the individualized treatment of patients at different risks.

Citing Articles

Exosome-mediated transfer of lncRNA RP3-340B19.3 promotes the progression of breast cancer by sponging miR-4510/MORC4 axis.

Wang B, Mao J, Wang L, Zhao Y, Wang B, Yang H Cancer Cell Int. 2024; 24(1):312.

PMID: 39256868 PMC: 11389435. DOI: 10.1186/s12935-024-03490-3.

A novel immune-related long noncoding RNA (lncRNA) pair model to predict the prognosis of triple-negative breast cancer.

Li J, Hu C, Peng H, Chen E Transl Cancer Res. 2024; 13(3):1252-1267.

PMID: 38617505 PMC: 11009803. DOI: 10.21037/tcr-23-1975.

The metabolism-related lncRNA signature predicts the prognosis of breast cancer patients.

Ge X, Lei S, Wang P, Wang W, Wang W Sci Rep. 2024; 14(1):3500.

PMID: 38347041 PMC: 10861477. DOI: 10.1038/s41598-024-53716-7.

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.

Arriaga-Canon C, Contreras-Espinosa L, Aguilar-Villanueva S, Bargallo-Rocha E, Garcia-Gordillo J, Cabrera-Galeana P Int J Mol Sci. 2023; 24(8).

PMID: 37108589 PMC: 10138835. DOI: 10.3390/ijms24087426.

Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.

Bahramy A, Zafari N, Rajabi F, Aghakhani A, Jayedi A, Khaboushan A Front Mol Biosci. 2023; 10:1096524.

PMID: 36726376 PMC: 9885171. DOI: 10.3389/fmolb.2023.1096524.

References

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Wang Y, Zhou W, Ma S, Guan X, Zhang D, Peng J . Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients. Front Oncol. 2021; 10:597877. PMC: 7892596. DOI: 10.3389/fonc.2020.597877. View

Du Y, Wei N, Ma R, Jiang S, Song D . Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1α Translation in Triple-Negative Breast Cancer. Front Oncol. 2021; 10:580176. PMC: 7774020. DOI: 10.3389/fonc.2020.580176. View

Li Y, Zhao Z, Liu W, Li X . SNHG3 Functions as miRNA Sponge to Promote Breast Cancer Cells Growth Through the Metabolic Reprogramming. Appl Biochem Biotechnol. 2020; 191(3):1084-1099. PMC: 7320061. DOI: 10.1007/s12010-020-03244-7. View

Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L . LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer. 2020; 19(1):85. PMC: 7206728. DOI: 10.1186/s12943-020-01206-5. View

Fiscon G, Paci P, Iannello G . MONSTER v1.1: a tool to extract and search for RNA non-branching structures. BMC Genomics. 2015; 16:S1. PMC: 4460781. DOI: 10.1186/1471-2164-16-S6-S1. View

Li S, Zhang Y, Dong J, Li R, Yu B, Zhao W . LINC00893 inhibits papillary thyroid cancer by suppressing AKT pathway via stabilizing PTEN. Cancer Biomark. 2020; 30(3):277-286. DOI: 10.3233/CBM-190543. View

Lai J, Chen B, Zhang G, Li X, Mok H, Liao N . Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature. J Transl Med. 2020; 18(1):416. PMC: 7648293. DOI: 10.1186/s12967-020-02578-4. View

Rivadeneira D, Delgoffe G . Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res. 2018; 24(11):2473-2481. PMC: 5984673. DOI: 10.1158/1078-0432.CCR-17-0894. View

10.

Koobotse M, Holly J, Perks C . Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines. Oncotarget. 2018; 9(71):33562-33576. PMC: 6173354. DOI: 10.18632/oncotarget.26093. View

11.

Camarda R, Williams J, Goga A . Reprogramming of Cancer Metabolism by MYC. Front Cell Dev Biol. 2017; 5:35. PMC: 5386977. DOI: 10.3389/fcell.2017.00035. View

12.

Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J . Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol. 2020; 235(12):9304-9316. DOI: 10.1002/jcp.29730. View

13.

Jiang M, Qiu N, Xia H, Liang H, Li H, Ao X . Long non‑coding RNA FOXD2‑AS1/miR‑150‑5p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol. 2019; 54(3):1043-1052. DOI: 10.3892/ijo.2019.4671. View

14.

Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X . Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids. 2020; 22:937-947. PMC: 7670249. DOI: 10.1016/j.omtn.2020.10.002. View

15.

Gandhi N, Das G . Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications. Cells. 2019; 8(2. PMC: 6406734. DOI: 10.3390/cells8020089. View

16.

Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C . Expression of Long Noncoding RNA Promotes Glycolysis in Breast Cancer. Cancer Res. 2018; 78(16):4524-4532. PMC: 6126676. DOI: 10.1158/0008-5472.CAN-17-0385. View

17.

Ma F, Liu X, Zhou S, Li W, Liu C, Chadwick M . Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. Cancer Lett. 2019; 450:63-75. DOI: 10.1016/j.canlet.2019.02.008. View

18.

Huang P, Xue J . Long non‑coding RNA FOXD2‑AS1 regulates the tumorigenesis and progression of breast cancer via the S100 calcium binding protein A1/Hippo signaling pathway. Int J Mol Med. 2020; 46(4):1477-1489. PMC: 7447301. DOI: 10.3892/ijmm.2020.4699. View

19.

Yousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Aref A, Momeny M . Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2019; 39(5):953-974. DOI: 10.1038/s41388-019-1040-y. View

20.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View